# CHEK1 Expression Correlates with Tumor Progression in Lung Adenocarcinoma but Not in Squamous Cell Carcinoma

**Authors:** Nahyeon Kim, Hyunbin Cha, Jun-Chae Lee, Jae-Ho Lee, Tae-Young Kim

PMC · DOI: 10.3390/medicina62020335 · 2026-02-06

## TL;DR

CHEK1 expression is linked to worse outcomes in lung adenocarcinoma but not in squamous cell carcinoma, suggesting it could be a useful biomarker for the former.

## Contribution

Identifies CHEK1 as a subtype-specific prognostic biomarker for lung adenocarcinoma but not squamous cell carcinoma.

## Key findings

- High CHEK1 expression correlates with advanced tumor stage and shorter survival in lung adenocarcinoma.
- CHEK1 expression does not significantly affect survival outcomes in squamous cell carcinoma.
- CHEK1 overexpression reflects tumor aggressiveness in lung adenocarcinoma.

## Abstract

Background and Objectives: Non-small cell lung cancer (NSCLC) is histologically divided into adenocarcinoma (AD) and squamous cell carcinoma (SCC). While Checkpoint kinase 1 (CHEK1) regulates the DNA damage response, its subtype-specific clinical impact in NSCLC remains unclear. We investigated the association of CHEK1 expression with clinicopathologic features and prognosis in AD and SCC. Materials and Methods: Transcriptomic and clinical data from 980 patients (492 AD, 488 SCC) were analyzed using The Cancer Genome Atlas (TCGA). Patients were stratified by median CHEK1 mRNA expression. Relationships between expression and clinicopathologic variables were evaluated via Chi-square tests, and overall survival (OS) was assessed using Kaplan–Meier analysis. Results: In AD, high CHEK1 expression significantly correlated with advanced T stage (p < 0.001), lymph node metastasis (p = 0.025), younger age (p = 0.017), and shorter OS (p = 0.025). Conversely, CHEK1 expression in SCC did not reach statistical significance for survival outcomes, although a borderline trend was observed (p = 0.067). Conclusions: CHEK1 is a subtype-specific prognostic biomarker for AD but not for SCC. These findings suggest that CHEK1 overexpression reflects tumor aggressiveness in AD, highlighting its potential as a therapeutic target for this specific population.

## Linked entities

- **Genes:** CHEK1 (checkpoint kinase 1) [NCBI Gene 1111]
- **Diseases:** adenocarcinoma (MONDO:0004970), squamous cell carcinoma (MONDO:0005096), non-small cell lung cancer (MONDO:0005233)

## Full-text entities

- **Genes:** EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, FGFR1 (fibroblast growth factor receptor 1) [NCBI Gene 2260] {aka BFGFR, CD331, CEK, ECCL, FGFBR, FGFR-1}, TERT (telomerase reverse transcriptase) [NCBI Gene 7015] {aka CMM9, DKCA2, DKCB4, EST2, PFBMFT1, TCS1}, CHEK1 (checkpoint kinase 1) [NCBI Gene 1111] {aka CHK1, OZEMA21}, KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, ATR (ATR checkpoint kinase) [NCBI Gene 545] {aka FCTCS, FRP1, MEC1, SCKL, SCKL1}, TENM1 (teneurin transmembrane protein 1) [NCBI Gene 10178] {aka ODZ1, ODZ3, TEN-M1, TEN1, TNM, TNM1}
- **Diseases:** lymph node metastasis (MESH:D008207), breast and colorectal cancers (MESH:D001943), ovarian cancer (MESH:D010051), metastasis (MESH:D009362), nodal (MESH:D013611), Lung Adenocarcinoma (MESH:D000077192), tumorigenesis (MESH:D063646), SCC (MESH:D002294), NSCLC (MESH:D002289), injury to (MESH:D014947), pancreatic cancer (MESH:D010190), AD (MESH:D000230), Cancer (MESH:D009369), lung cancer (MESH:D008175)
- **Chemicals:** LY2606368 (MESH:C000608121), AZD7762 (MESH:C532363)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12941936/full.md

---
Source: https://tomesphere.com/paper/PMC12941936